EP Patent

EP2659890A1 — Methods and compositions for the treatment of fibrosis

Assigned to Orphan Synergy Europe - Pharma · Expires 2013-11-06 · 13y expired

What this patent protects

This invention relates to tritoqualine for use in the treatment of cystic fibrosis or any other fibrosis disease associated with IL-8. The invention also relates to the method for the treatment of cystic fibrosis or any other fibrosis disease associated with IL-8 by administering…

USPTO Abstract

This invention relates to tritoqualine for use in the treatment of cystic fibrosis or any other fibrosis disease associated with IL-8. The invention also relates to the method for the treatment of cystic fibrosis or any other fibrosis disease associated with IL-8 by administering tritoqualine. The invention can be used to improve the condition of individuals with any fibrosis disease associated with IL-8, and in particular cystic fibrosis.

Drugs covered by this patent

Patent Metadata

Patent number
EP2659890A1
Jurisdiction
EP
Classification
—
Expires
2013-11-06
Drug substance claim
No
Drug product claim
No
Assignee
Orphan Synergy Europe - Pharma
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.